Show simple item record

dc.contributor.authorFlume, Patrick A.
dc.contributor.authorO'Sullivan, Brian P.
dc.contributor.authorRobinson, Karen A.
dc.contributor.authorGoss, Christopher H.
dc.contributor.authorMogayzel, Peter J. Jr.
dc.contributor.authorWilley-Courand, Donna Beth
dc.contributor.authorBujan, Janet
dc.contributor.authorFinder, Jonathan
dc.contributor.authorLester, Mary
dc.contributor.authorQuittell, Lynne
dc.contributor.authorRosenblatt, Randall
dc.contributor.authorVender, Robert L.
dc.contributor.authorHazle, Leslie
dc.contributor.authorSabadosa, Kathy
dc.contributor.authorMarshall, Bruce
dc.date2022-08-11T08:10:14.000
dc.date.accessioned2022-08-23T17:00:27Z
dc.date.available2022-08-23T17:00:27Z
dc.date.issued2007-11-15
dc.date.submitted2012-01-11
dc.identifier.citationAm J Respir Crit Care Med. 2007 Nov 15;176(10):957-69. Epub 2007 Aug 29. <a href="http://dx.doi.org/10.1164/rccm.200705-664OC">Link to article on publisher's site</a>
dc.identifier.issn1073-449X (Linking)
dc.identifier.doi10.1164/rccm.200705-664OC
dc.identifier.pmid17761616
dc.identifier.urihttp://hdl.handle.net/20.500.14038/43799
dc.description.abstractRATIONALE: Cystic fibrosis is a recessive genetic disease characterized by dehydration of the airway surface liquid and impaired mucociliary clearance. As a result, individuals with the disease have difficulty clearing pathogens from the lung and experience chronic pulmonary infections and inflammation. Death is usually a result of respiratory failure. Newly introduced therapies and aggressive management of the lung disease have resulted in great improvements in length and quality of life, with the result that the median expected survival age has reached 36 years. However, as the number of treatments expands, the medical regimen becomes increasingly burdensome in time, money, and health resources. Hence, it is important that treatments should be recommended on the basis of available evidence of efficacy and safety. OBJECTIVES: The Cystic Fibrosis Foundation therefore established a committee to examine the clinical evidence for each therapy and to provide guidance for the prescription of these therapies. METHODS: The committee members developed and refined a series of questions related to drug therapies used in the maintenance of pulmonary function. We addressed the questions in one of three ways, based on available evidence: (1) commissioned systematic review, (2) modified systematic review, or (3) summary of existing Cochrane reviews. CONCLUSIONS: It is hoped that the guidelines provided in this article will facilitate the appropriate application of these treatments to improve and extend the lives of all individuals with cystic fibrosis.
dc.language.isoen_US
dc.relation<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Retrieve&list_uids=17761616&dopt=Abstract">Link to Article in PubMed</a>
dc.relation.urlhttp://dx.doi.org/10.1164/rccm.200705-664OC
dc.subjectAnti-Asthmatic Agents
dc.subjectAnti-Bacterial Agents
dc.subjectAnti-Inflammatory Agents
dc.subjectChild
dc.subjectCystic Fibrosis
dc.subjectDeoxyribonuclease I
dc.subjectHumans
dc.subjectAllergy and Immunology
dc.subjectPediatrics
dc.subjectRespiratory Tract Diseases
dc.titleCystic fibrosis pulmonary guidelines: chronic medications for maintenance of lung health
dc.typeJournal Article
dc.source.journaltitleAmerican journal of respiratory and critical care medicine
dc.source.volume176
dc.source.issue10
dc.identifier.legacycoverpagehttps://escholarship.umassmed.edu/peds_pulmonary/15
dc.identifier.contextkey2441375
html.description.abstract<p>RATIONALE: Cystic fibrosis is a recessive genetic disease characterized by dehydration of the airway surface liquid and impaired mucociliary clearance. As a result, individuals with the disease have difficulty clearing pathogens from the lung and experience chronic pulmonary infections and inflammation. Death is usually a result of respiratory failure. Newly introduced therapies and aggressive management of the lung disease have resulted in great improvements in length and quality of life, with the result that the median expected survival age has reached 36 years. However, as the number of treatments expands, the medical regimen becomes increasingly burdensome in time, money, and health resources. Hence, it is important that treatments should be recommended on the basis of available evidence of efficacy and safety.</p> <p>OBJECTIVES: The Cystic Fibrosis Foundation therefore established a committee to examine the clinical evidence for each therapy and to provide guidance for the prescription of these therapies.</p> <p>METHODS: The committee members developed and refined a series of questions related to drug therapies used in the maintenance of pulmonary function. We addressed the questions in one of three ways, based on available evidence: (1) commissioned systematic review, (2) modified systematic review, or (3) summary of existing Cochrane reviews.</p> <p>CONCLUSIONS: It is hoped that the guidelines provided in this article will facilitate the appropriate application of these treatments to improve and extend the lives of all individuals with cystic fibrosis.</p>
dc.identifier.submissionpathpeds_pulmonary/15
dc.contributor.departmentDepartment of Pediatrics
dc.source.pages957-69


This item appears in the following Collection(s)

Show simple item record